

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Respectfully submitted,

  
\_\_\_\_\_  
Anthony J. Zelano, Reg. No. 27,969  
Attorney for Applicants  
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Boulevard, Suite 1400  
Arlington, VA 22201  
Direct Dial: 703-812-5311  
Facsimile: 703-243-6410  
Email: zelano@mwzb.com

AJZ:jmm

FILED: 14 JUNE 2001

09868098.061401

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 7, 10-11, 13 and 15 have been amended as follows:

7. (Amended) Peptide compounds of the formula I or II according to Claims 1 to 6 and their physiologically acceptable salts as medicaments.

10. (Amended) Pharmaceutical preparation comprising at least one medicament according to ~~one of~~ Claims 7 to 9 and, if appropriate, vehicles and/or excipients and, if appropriate, other active compounds.

11. (Amended) Use of peptide compounds according to Claims 1 to 6 and/or their physiologically acceptable salts for the production of a medicament for controlling disorders which are based on an expression and pathological function of  $\alpha_v\beta_6$  integrin receptors.

13. (Amended) Recombinant DNA comprising a sequence which codes for a peptide section which corresponds to a peptide compound of Claims 1-6.

15. (Amended) Virus, characterized in that it possesses a coat protein which has a sequence which corresponds to a peptide compound of Claims 1-6.